Related Experiment Video
Updated: Jun 22, 2026

09:05
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
Published on: May 4, 2015
Myocardial infarct size and cardiogenic shock
European Heart Journal
|May 1, 1983
Summary
Cardiogenic shock in acute myocardial infarction (AMI) patients is linked to larger infarct sizes, but significant overlap exists. Even small infarcts can cause shock, particularly with other cardiac issues.
Area of Science:
- Cardiology
- Cardiovascular Research
- Medical Science
Background:
- Cardiogenic shock is a severe complication of acute myocardial infarction (AMI).
- The precise relationship between infarct size and the development of cardiogenic shock requires further elucidation.
Purpose of the Study:
- To investigate the association between estimated infarct size and the occurrence of cardiogenic shock in patients with AMI.
- To explore the role of infarct characteristics in mortality among shock patients.
Main Methods:
- In vivo infarct size estimation using serum CK-MB levels in 317 AMI patients.
- Histological and histochemical analysis of heart autopsy in 23 non-survivors.
- Comparison of infarct sizes between patients with and without cardiogenic shock.
Main Results:
- Patients with cardiogenic shock exhibited a significantly larger median infarct size (1035 U/l) compared to those without shock (669 U/l).
- A substantial overlap in infarct size was observed between the two groups.
- Autopsy findings revealed that even small subendocardial infarcts could lead to shock, especially in the presence of severe coronary artery disease or infarction fibrosis.
Conclusions:
- While larger infarct size is associated with cardiogenic shock in AMI, it is not the sole determinant.
- Infarct size in survivors of cardiogenic shock and those who died from shock was similar.
- Mortality from shock was comparable to mortality from other cardiac causes, irrespective of infarct size.
Related Concept Videos
Blood Pressure Imbalances and Circulatory Shock
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

